OptimizeRx (NASDAQ:OPRX) Cut to “Buy” at Wall Street Zen

Wall Street Zen cut shares of OptimizeRx (NASDAQ:OPRX) from a strong-buy rating to a buy rating in a research note released on Monday.

OPRX has been the topic of several other research reports. UBS Group set a $10.00 price target on shares of OptimizeRx in a research note on Wednesday, May 13th. Stifel Nicolaus lowered their price objective on shares of OptimizeRx from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Lake Street Capital dropped their target price on shares of OptimizeRx from $20.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Stephens dropped their target price on shares of OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 13th. Finally, Zacks Research lowered shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 4th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $13.43.

OptimizeRx Price Performance

OPRX opened at $6.46 on Monday. The business has a fifty day moving average of $5.51 and a 200 day moving average of $7.39. The stock has a market cap of $121.19 million, a P/E ratio of 18.46 and a beta of 1.08. The company has a quick ratio of 5.37, a current ratio of 5.37 and a debt-to-equity ratio of 0.16. OptimizeRx has a 52-week low of $4.54 and a 52-week high of $22.25.

OptimizeRx (NASDAQ:OPRX) last released its earnings results on Tuesday, May 12th. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The business had revenue of $19.84 million for the quarter, compared to analyst estimates of $18.74 million. OptimizeRx had a return on equity of 10.86% and a net margin of 6.37%. As a group, sell-side analysts anticipate that OptimizeRx will post 0.51 EPS for the current year.

Hedge Funds Weigh In On OptimizeRx

Institutional investors have recently made changes to their positions in the company. Next Century Growth Investors LLC raised its holdings in shares of OptimizeRx by 139.8% in the 4th quarter. Next Century Growth Investors LLC now owns 505,407 shares of the company’s stock valued at $6,196,000 after purchasing an additional 294,688 shares in the last quarter. Rice Hall James & Associates LLC boosted its stake in shares of OptimizeRx by 1.9% during the first quarter. Rice Hall James & Associates LLC now owns 601,921 shares of the company’s stock valued at $3,780,000 after purchasing an additional 11,247 shares in the last quarter. State of Wyoming boosted its stake in shares of OptimizeRx by 234.6% during the first quarter. State of Wyoming now owns 35,251 shares of the company’s stock valued at $221,000 after purchasing an additional 24,716 shares in the last quarter. Principal Financial Group Inc. increased its holdings in OptimizeRx by 131.7% during the first quarter. Principal Financial Group Inc. now owns 63,790 shares of the company’s stock valued at $401,000 after buying an additional 36,259 shares during the period. Finally, Hsbc Holdings PLC purchased a new position in OptimizeRx during the first quarter valued at approximately $85,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.